Introduction {#S1}
============

Annually, nearly 800,000 individuals are admitted to an intensive care unit (ICU) on mechanical ventilation at the cost of over 27 billion dollars ([@B5]). Of those who survive, many will go on to experience posttraumatic stress disorder (PTSD; [@B15];[@B16]). Posttraumatic stress disorder is a mental health condition that may develop in individuals who experience or witness a traumatic, life-threatening event and is characterized by re-experiencing, hyperarousal, avoidance, memory impairment, flashbacks, mood labiality, and hypervigilance ([@B1]). Although critical illness treatments are aimed at sustaining life, they can be stressful, and can include a range of terrifying experiences such as respiratory insufficiency, loss of ability to communicate, and may include altered cognition, hallucinations and delusions ([@B8]). Potential risk factors for the development of PTSD after the ICU include: pre-morbid psychiatric history, sedation, mechanical ventilation, physical restraints, delirium, delusional memories, loss of control, and agitation ([@B18]).

To our knowledge, no neuroimaging studies have explored the association between post-traumatic stress and neurological changes *in survivors of the ICU*, although this has been well-studied in other populations, which have implicated several key brain regions in the development of the disorder including the hippocampus, amygdala, and the prefrontal cortex ([@B9]; [@B19]; [@B13]). [@B19] metanalysis of 39 volumetric studies found lower hippocampal volumes in both subjects with PTSD and trauma-exposed subjects without a PTSD diagnosis. In a large study of veterans, subjects with PTSD had a smaller volume for both the right and left amygdala ([@B12]).

By understanding more about PTSD pathophysiology, further steps can be taken to attempt to prevent or treat PTSD ([@B10]). The purpose of this investigation is to explore the severity of posttraumatic stress symptoms in association with hippocampal and amygdala volumes in survivors of the ICU. We hypothesize that the severity of posttraumatic stress symptoms in ICU survivors is associated with lower volumes of both the hippocampus and amygdala.

Methods {#S2}
=======

We undertook a secondary analysis of the VISIONS (VISualizing Icu SurvivOrs Neuroradiological Sequelae) study ([@B4]), a prospective convenience sample sub-study of the BRAIN-ICU cohort ([@B14]). The IRB at Saint Thomas Hospital and Vanderbilt University approved the study protocol. Enrolled patients had survived ICU treatment with mechanical ventilation or vasopressors in the context of severe critical illness and were agreeable to participate in this neuroimaging sub-study.

To be eligible to participate in the study, adult patients had to meet the following criteria: surviving in the ICU in cardiac, surgical, or medical ICU at Saint Thomas Hospital or Vanderbilt University Hospital, both located in Nashville, TN. The exclusion criteria were as follows: deafness, blindness, delirium at hospital discharge, dementia, anoxic brain injury, TBI, known brain lesions, MRI contraindications, claustrophobia, and weight of more than 300 pounds.

Patients were screened for preexisting PTSD before they left the hospital. The PTSD Checklist Specific (PCL-S; [@B3]) was used to identify a traumatic event and categorized severity based on their score. The PCL-S was used at 3 and 12 months after discharge to evaluate the ICU as a traumatic experience. Our PTSD threshold was a PCL-S score of greater than or equal to 30, as we wanted to capture all possible patients with significant symptoms of PTSD ([@B11]).

A Philips Achieva 3T MRI scanner was used to scan patients at both discharge and 3 month follow-up. Scanning included T1-weighted 3D turbo field echo image covering the whole brain, 170 slices, TR = 8.0 ms, TE = 3.7 ms, SENSE factor = 2, voxel size = 1 mm isotropic, FOV = 256 × 256 × 170. Study staff computed the regional volumes with an established software pipeline, without adjusting any parameter settings, in particular, without adjusting settings after reviewing the results. A multi-atlas segmentation algorithm ([@B2]) using a set of 45 manually labeled atlases (Neuromorphometrics, Inc., Somerville, MA, United States) was applied to parcellate each person's T1-weighted structural image. The regions extracted followed brainCOLOR and included hippocampus, amygdala, and total intracranial volume. The hippocampus and amygdala regions were further refined using a multi-scale approach based on an additional set of atlases ([@B17]). The data was also visually inspected to ensure accuracy.

Study data were collected and managed using REDCap electronic data capture tools hosted at Vanderbilt University ([@B7], [@B6]). Amygdala and hippocampal volumes were defined as right plus left hemispheres for each respective structure. To compare median brain volumes at discharge and 3 months for those with and without significant PTSD symptomatology (PCL-S = 30) at 3 and 12 months, we used a Kruskal--Wallis (KW) equality-of-populations rank test.

Results {#S3}
=======

The median age for our sample was 58.5 (52.6, 63.7) ([Table 1](#T1){ref-type="table"}). One-third of the sample was female, and 90% were Caucasian. Fifty-seven percent of individuals (*N* = 12) had at least 1 prior mental health diagnosis, with *N* = 2 having a prior history of PTSD. One-third of individuals experienced delirium during their critical illness. At 3 month follow up, there were three patients with PTSD symptomatology and *N* = 1 at 12 month follow up. Hippocampal and amygdala volumes at discharge and 3 month follow-up are reported in [Table 1](#T1){ref-type="table"}. There was no difference between median brain volumes (hippocampus or amygdala) between individuals with PTSD symptomatology at either 3 or 12 months (*p*-values for all tests \> 0.05).

###### 

Patient demographic and clinical characteristics.

  **Variable**                                       ***N* (%) or median (IQR)\***
  -------------------------------------------------- -------------------------------
  **Age (years)**                                    58.5 (52.6, 63.7)
  **Gender**                                         
  Female                                             7 (33%)
  Male                                               14 (67%)
  **Race**                                           
  Black/African American                             2 (10%)
  White/Caucasian                                    19 (90%)
  **ICU type**                                       
  Medical                                            10 (48%)
  Surgical                                           11 (52%)
  **Charlson comorbidity index**                     1 (1, 3)
  **SOFA score (at enrollment)**                     10 (8, 12)
  **Diagnosis at admission**                         
  Sepsis/ARDS due to infection or septic shock       7 (33%)
  ARDS without infection                             2 (10%)
  CHF/Cardiogenic shock                              1 (5%)
  Hepatobiliary/pancreatic surgery                   6 (29%)
  COPD/Asthma                                        3 (14%)
  Vascular surgery                                   2 (10%)
  **Delirium**                                       
  Number of patients with delirium                   13 (62%)
  Length of delirium (in days, for those affected)   1 (1, 5)
  **Preexisting mental health diagnosis**            
  PTSD                                               2 (10%)
  Alcohol use disorder                               3 (14%)
  Depression                                         10 (48%)
  Bipolar disorder                                   1 (5%)
  Personality disorder                               1 (5%)
  **ICU length of stay (days)**                      4 (1, 5)
  **Hospital length of stay (days)**                 9 (6, 12)
  **PTSD (yes, score = 30)**                         
  3 month follow up (*N* = 21)                       3 (14%)
  12 month follow up (*N* = 13)                      1 (8%)
  **PCL total score**                                
  3 month follow up                                  19 (18, 24)
  12 month follow up                                 20 (17, 28)
  **Amygdala volume (total volume; mm^3^)**          
  discharge                                          2110 (2004, 2205)
  3 month follow up                                  2079 (1921, 2192)
  **Hippocampus volume (total volume; mm^3^)**       
  discharge                                          5779 (5359, 6101)
  3 month follow up                                  5674 (5182, 6240)

\*IQR, Interquartile range. \*\*

N

= 21 is the group of patients who had both a MRI at discharge and a 3 month PCL-S complete. Only

N

= 13 had both a 3 month MRI and 12 month PCL. Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24 (from 0 to 4 for each of six organ systems), with higher scores indicating more severe organ dysfunction. We used a modified SOFA score, which excluded the Glasgow Coma Scale components, since coma was included separately in our models. Scores on the Charlson comorbidity index range from 0 to 33, with higher scores indicating a greater burden of illness; a score of 1 or 2 is associated with mortality of approximately 25% at 10 year. ARDS, Acute Respiratory Distress Syndrome; CHF, Congestive Heart Failure; COPD, Chronic Obstructive Pulmonary Disease.

Discussion {#S4}
==========

Millions of Americans are admitted to the ICU per year -- nearly 800,000 of which are on mechanical ventilation ([@B5]). Many survivors will develop PTSD, and although volumetric neurological studies have been conducted in veterans and other trauma survivors, the association between PTSD symptoms and hippocampal and amygdala volumes in ICU survivors has not yet been studied before this secondary analysis. We hypothesized that the severity of posttraumatic stress symptoms in ICU survivors is associated with lower volumes of both the hippocampus and amygdala at 3 and 12 months. Using a secondary analysis of the VISIONS study, we found at 3 month follow up, three patients had PTSD symptomatology and *N* = 1 at 12 month follow up. We did not find a significant difference between median brain volumes (hippocampus or amygdala) between individuals with PTSD symptomatology at either 3 or 12 months.

Although our study did not reveal significant differences in brain volumes between PTSD patients and non-PTSD patients, sample size was a major limitation and larger scale studies should be undertaken to elucidate possible neurobiological markers of PTSD in ICU survivors. Large metanalyses and studies in veterans have revealed trauma exposure and PTSD can lead to lower volumes in both the hippocampus and amygdala ([@B19]; [@B12]). Additionally, by using a less conservative threshold for PTSD on the PCL, we cannot say for certain that patients in our sample had PTSD. With a larger scale study, more conservative cut points (e.g., \>50) could be employed. Additionally, we do not have imaging pre-critical illness; thus, we cannot know whether brain volumes were directly related to their critical illness.

Further studies should investigate the role of sedation in the evolution of delirium and PTSD. More research is needed to investigate the neurological changes in ICU survivors with PTSD, to understand the pathophysiology of the disease, inform clinical treatment of survivors, and aid in understanding risk factors ([@B16]).
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